Dr.Roberto Collazo-Maldonado

We’re proud to share that Dr. Alexander Liang represented Dallas Nephrology Associates as a panel speaker at the Texas Association of Accountable Care Organizations conference held May 4–6.

El consumo de suplementos de creatina son seguros para el riñón, el incremento observado en las cifras de creatinina sérica (↑0.13mg/dL) es por generar mayor metabolismo de la misma, no por daño renal Metaaanalsis 20 ensayos clínicos J Ren Nutr 2026 10.1053/j.jrn.2026.04.010

Happy Mother's Day to all the mothers out there! Thank you for all you do!

Representing Methodist Dallas and presenting my posters at NKF Spring Clinical meeting 2026 @ NOLA. Thanks to my mentors for making it possible (Dr Collazo and Dr Sebastian). #NKFClinicals #SCM2026

POCUS time! #NKFClinicals #SCM #SCM2026

@NephRodby @Nephro_Sparks @rmohty Agree.We know for sure that ‘low phosphate’ is a bad.

@Nephro_Sparks @rmohty I have such “high” hopes for the PHOSPHATE trial, and secretly (I guess not now) hoping that high PO4 within reason is not bad. We spend so much time and money and guilt on that anion with little evidence that it is modifiable risk factor.

Dr Wald now hitting the most unsatisfying practice in nephrology. Phosphate normalization in patients on dialysis The ongoing PHOSPHATE trial #NKFClinicals

Happy National Nurses Week! 💙 Dallas Nephrology Associates honors the compassion, skill, and dedication of our nurses who care for patients every day. Thank you for all you do. 💙 #NationalNursesWeek #ThankYouNurses

@ISNkidneycare @kidney_boy What a great choice 👌.Gifted teacher and outstanding leader of Nephrology.

Jai Radhakrishnan, MD, has been named the next Editor-in-Chief of Kidney International®, ISN’s flagship journal. Currently Editor-in-Chief of Kidney International Reports®, he will take on the role in January 2027, building on his leadership across the ISN journals portfolio. Read more: bit.ly/3P1WW9h #ThisIsISN #Nephrology #MedicalResearch

30-60% of #HeartFailure patients also have #CKD, & this overlap markedly increases the risk of hospitalization🏥 & death☠️ Despite major advances in each condition, important gaps remain when they coexist⚠️: diagnosis is challenging, biomarkers are harder to interpret, & management is less straightforward This @goKDIGO executive conclusions brought experts together to tackle these challenges
 Here are the key takeaways👇
📄 #JACCHF: jacc.org/doi/10.1016/j.… @JACCJournals @lamcardio @BiykemB @JustinEzekowitz @jardine_meg @jozinetm @HeartDocSadiya @NishaKidneyDoc

The entire May 2026 issue of AJKD is FREE until the end of the month to celebrate #NKFClinicals! Check out the plain-language summaries on what inspired each study, the basic approach taken, what was learned, and why it matters: bit.ly/AJKDMay26Highl… @NKF_NephPros

Finerenone vs spironolactone

OMG! It finally happened! Dapa is $8/month at @costplusdrugs #Flozinator Thank you @mcuban

🚨A new @KIReports Community blog about Obinutuzumab. Wonderful review of how it differs from other anti-CD20 treatments, worth a read 📖 By @drpriyajohn #NephTwitter #MedTwitter kireportscommunity.org/post/beyond-ri…

🧪 ¿Y el volumen de orina? Los resultados confirman la eficacia. La infusión continua (FC), los iSGLT2 y el tolvaptán mostraron una producción de orina significativamente mayor que los bolos intermitentes. 🚽⬆️

Now available! Generic dapagliflozin 10 mg 30 day supply, direct cash price $8.36 @ACCinTouch @HFSA @American_Heart @AAHFN @SJGreene_md @ATSandhu @boback @NMHheartdoc @docsabe @HeartDocSadiya

💥 Should we start SGLT2i DURING hospitalization for acute heart failure? 🔍 New systematic review & meta-analysis: 8 RCTs | n = 4,096 patients ✅ In-hospital SGLT2i initiation significantly reduces: • All-cause death → RR 0.61 (95% CI 0.47–0.81) • Worsening HF events → RR 0.67 (95% CI 0.45–0.94) • Cardiovascular death → RR 0.68 (95% CI 0.47–0.99) 🟡 No significant reduction in HF rehospitalization (RR 0.87) ⚠️ No increase in acute kidney injury or serious adverse events 💡 Key message: early in-hospital initiation of SGLT2i is safe and reduces mortality — don’t wait for discharge! 📄 Ahmed et al. Journal of Cardiac Failure, 2026 #Cardiology #HeartFailure #SGLT2i #AcuteHF #GDMT #CardioTwitter

Congratulations to Elizabeth Chen, Ph.D., Ralph DeBerardinis, M.D., Ph.D., and Joel Elmquist, D.V.M., Ph.D., on their election to @theNASciences. UTSW now has 27 NAS members, more than all other institutions in Texas and the most in UT Southwestern history.

Meta-analysis of SGLT2 inhibitors 18 RCTs including 95,913 patients 🫀 Reduce CV mortality 🩺 Improve kidney outcomes 📉 Lower overall mortality risk Benefits seen in diabetes, heart failure & CKD — with signals of added survival benefit across age groups. A true cornerstone of cardiorenal protection. sciencedirect.com/science/articl…